Sjogren’s Syndrome Market is Projected to Grow Significantly by 2036 Owing to the Launch of Emerging Disease-Modifying Therapies | DelveInsight

Posted on
by

Sjogren’s Syndrome Market is Projected to Grow Significantly by 2036 Owing to the Launch of Emerging Disease-Modifying Therapies | DelveInsight
The market dynamics for Sjogren’s Syndrome are witnessing steady growth driven by the increasing prevalence of autoimmune disorders, rising awareness regarding early diagnosis, growing burden of chronic dry eye and dry mouth conditions, and increasing demand for effective disease-modifying therapies. Additionally, the launch of emerging therapies such as Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, and others will further fuel the market.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Sjogren’s Syndrome Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Sjogren’s Syndrome, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Sjogren’s Syndrome Market

  • The market size for Sjogren’s Syndrome in the leading markets is expected to grow significantly by 2036.

  • The United States accounted for the highest Sjogren’s Syndrome treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.

  • As per DelveInsight’s analysis, in 2025, the total diagnosed prevalent cases of Sjogren’s Syndrome were approximately 3,350,000 in the 7MM, which are expected to increase during the forecast period, i.e., 2026–2036.

  • In 2025, the diagnosed prevalent cases of Sjogren’s Syndrome were the highest in the US accounting for approximately 1,800,000 cases which are estimated to increase by 2036.

  • According to the Sjogren’s Syndrome Foundation (US), it is one of the second most common autoimmune rheumatic diseases, striking as many as 4,000,000 Americans.

  • Approximately one percent of the US population is affected with Sjogren’s Syndrome, wherein mostly adult women are affected. Nine out of 10 patients are women.

  • According to the study conducted by Stefanski et al. (2017), the overall prevalence of Sjogren’s Syndrome, including the more common secondary form of the disease, is estimated to be at least 0.4% in Germany.

  • According to the Japan Intractable Diseases Information Center, approximately 68,000 patients were admitted to hospitals for one year for Sjogren’s Syndrome in Japan.

  • Leading Sjogren’s Syndrome companies such as Novartis, Amgen, Vor Bio, Resolve Therapeutics, Johnson & Johnson, and others are developing new Sjogren’s Syndrome treatment drugs that can be available in the Sjogren’s Syndrome market in the coming years.

  • The promising Sjogren’s Syndrome therapies in clinical trials include Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, RSLV-132, AMG 329, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/sjogrens-syndrome-market-size

Key Factors Driving the Sjogren’s Syndrome Market

  • Rising Disease Prevalence and Awareness: Increasing diagnosis rates, growing awareness regarding autoimmune diseases, and advancements in diagnostic approaches are helping identify more Sjogren’s Syndrome patients globally.

  • Increasing Demand for Effective Disease-Modifying Therapies: Currently available therapies mainly focus on symptom management, creating a strong demand for disease-modifying therapies capable of improving long-term outcomes and reducing systemic complications.

  • Growing Focus on Biological Therapies and Novel Mechanisms: Several emerging therapies targeting BAFF, CD40L, FcRn, and APRIL pathways are being developed to improve disease management and reduce inflammatory burden in Sjogren’s Syndrome patients.

  • Advancements in Diagnostic and Supportive Care Approaches: Improved use of salivary gland biopsy, salivary gland ultrasound, and biomarker-driven diagnosis are contributing to better disease detection and treatment optimization.

Sjogren’s Syndrome Competitive Landscape

  • Several Sjogren’s Syndrome drugs in development include Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, RSLV-132, and AMG 329.

  • These candidates target diverse mechanisms such as BAFF-R inhibition and ADCC-mediated B-cell depletion, CD40 ligand inhibition, BAFF/APRIL targeting, anti-FcRn mechanisms, and RNAse therapy, aiming to improve symptoms and disease progression with better efficacy and safety profiles than current treatment options.

Discover more about therapies set to grab major Sjogren’s Syndrome market share @ Sjogren’s Syndrome Treatment Landscape

Recent Developments in the Sjogren’s Syndrome Market

  • In March 2025, Johnson & Johnson announced that the US FDA granted investigational nipocalimab Fast Track designation for the treatment of adult patients with moderate-to-severe Sjogren’s disease.

  • In November 2023, Amgen presented new data from the Phase II trial of dazodalibep in Sjogren’s Syndrome at ACR 2023.

  • In June 2025, Vor Bio and RemeGen announced an exclusive license agreement granting Vor Bio global rights to develop and commercialize telitacicept outside China, Hong Kong, Macau, and Taiwan.

  • Ianalumab (VAY736) developed by Novartis is currently in Phase III developmental stage for Primary Sjogren’s Syndrome.

What is Sjogren’s Syndrome?

Sjogren’s Syndrome is a chronic autoimmune disorder characterized by the immune system attacking moisture-producing glands, leading primarily to dry eyes and dry mouth. The disease can also affect multiple organs including joints, lungs, kidneys, nerves, and blood vessels. Patients commonly experience fatigue, joint pain, dental complications, and an increased risk of lymphoma. Disease severity varies significantly among individuals, ranging from mild glandular involvement to severe systemic manifestations.

Sjogren’s Syndrome Epidemiology Segmentation

The Sjogren’s Syndrome epidemiology section provides insights into the historical and current Sjogren’s Syndrome patient pool and forecasted trends for the leading markets. The Sjogren’s Syndrome market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

  • Total Diagnosed Prevalent Cases of Sjogren’s Syndrome

  • Type-specific Cases of Sjogren’s Syndrome

  • Gender-specific Cases of Sjogren’s Syndrome

  • Severity-specific Cases of Sjogren’s Syndrome

  • Antigen-specific Cases of Sjogren’s Syndrome

  • Total Treated Cases of Sjogren’s Syndrome

Scope of the Sjogren’s Syndrome Market Report

  • Therapeutic Assessment: Sjogren’s Syndrome current marketed and emerging therapies

  • Sjogren’s Syndrome Market Dynamics: Key Market Forecast Assumptions of Emerging Sjogren’s Syndrome Drugs and Market Outlook

  • Key Companies: Novartis, Amgen, Vor Bio, Resolve Therapeutics, Johnson & Johnson, and others

  • Key Therapies: Ianalumab (VAY736), Dazodalibep (VIB4920), Telitacicept, Nipocalimab, RSLV-132, AMG 329, SALAGEN, EVOXAC, and others

  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

  • Unmet Needs, KOL’s views, Analyst’s views, Sjogren’s Syndrome Market Access and Reimbursement

To know more about Sjogren’s Syndrome companies working in the treatment market, visit @ Sjogren’s Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

  1. Sjogren’s Syndrome Market Report Introduction

  2. Executive Summary for Sjogren’s Syndrome

  3. SWOT Analysis of Sjogren’s Syndrome

  4. Sjogren’s Syndrome Patient Share (%) Overview at a Glance

  5. Sjogren’s Syndrome Market Overview at a Glance

  6. Sjogren’s Syndrome Background and Overview

  7. Sjogren’s Syndrome Epidemiology and Patient Population

  8. Country-Specific Patient Population of Sjogren’s Syndrome

  9. Sjogren’s Syndrome Current Treatment and Medical Practices

  10. Sjogren’s Syndrome Unmet Needs

  11. Sjogren’s Syndrome Emerging Therapies

  12. Sjogren’s Syndrome Market Outlook

  13. Country-Wise Sjogren’s Syndrome Market Analysis (2022–2036)

  14. Sjogren’s Syndrome Market Access and Reimbursement of Therapies

  15. Sjogren’s Syndrome Market Drivers

  16. Sjogren’s Syndrome Market Barriers

  17. Sjogren’s Syndrome Appendix

  18. Sjogren’s Syndrome Report Methodology

  19. DelveInsight Capabilities

  20. Disclaimer

  21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services